Kazuo Fujihara, Jeffrey L. Bennett, Jerome de Seze, Masayuki Haramura, Ingo Kleiter, Brian G. Weinshenker, Delene Kang, Tabasum Mughal, Takashi Yamamura. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2020. 7. 5
Janine Beekman, Aysha Keisler, Omar Pedraza, Masayuki Haramura, Athos Gianella-Borradori, Eliezer Katz, John N. Ratchford, Gerard Barron, Lawrence J. Cook, Jacinta M. Behne, et al. Neuromyelitis optica spectrum disorder Patient experience and quality of life. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2019. 6. 4. e580
Miyuki Mabuchi, Tadashi Shimizu, Masayuki Haramura, Akito Tanaka. Identification and purification of target protein using affinity resin bearing a photo-labile linker. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2015. 25. 16. 3373-3377
Kohji Nagano, Takashi Shinkawa, Kuniyasu Kato, Noriyuki Inomata, Nami Yabuki, Masayuki Haramura. Distinct cell surface proteome profiling by biotin labeling and glycoprotein capturing. JOURNAL OF PROTEOMICS. 2011. 74. 10. 1985-1993
Kohji Nagano, Takashi Shinkawa, Nami Yabuki, Hironori Mutoh, Noriyuki Inomata, Yoshinori Watanabe, Motooki Ashihara, Shigehisa Nagahashi, Nobuya Ishii, Yuko Aoki, et al. Integration of proteomic analyses to monitor the activity status of phosphorylation signaling. JOURNAL OF PROTEOMICS. 2011. 74. 3. 319-326
Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching-Piao Tsai, Albert Saiz, Masayuki Haramura, et al. Efficacy of Satralizumab (SA237) in Subgroups of Patients in SakuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). MULTIPLE SCLEROSIS JOURNAL. 2020. 26. 9. NP39-NP39
荒木 学, 藤原 一男, 原村 昌幸, 寺田 悠介, 河田 祐一, 山村 隆, the SAkuraSky and SAkuraStar study authors and investigators. MS/NMO1 Satralizumabの有効性と安全性 NMOSD患者に対する二重盲検プラセボ対照P3研究(MS/NMO 1 Efficacy and safety of satralizumab: double-blind placebo-controlled P3 studies in NMOSD patients). 神経免疫学. 2019. 24. 1. 105-105
Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching Piao Tsai, Albert Saiz, Masayuki Haramura, et al. Efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD). NEUROLOGY. 2019. 92. 15